CytoMed Therapeutics Past Earnings Performance
Past criteria checks 0/6
CytoMed Therapeutics's earnings have been declining at an average annual rate of -30.4%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 72.1% per year.
Key information
-30.4%
Earnings growth rate
-15.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 72.1% |
Return on equity | -36.8% |
Net Margin | -814.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How CytoMed Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -4 | 0 | 2 |
30 Sep 23 | 1 | -4 | 0 | 2 |
30 Jun 23 | 1 | -4 | 0 | 2 |
31 Mar 23 | 0 | -4 | 0 | 2 |
31 Dec 22 | 0 | -3 | 0 | 2 |
30 Sep 22 | 0 | -3 | 0 | 1 |
30 Jun 22 | 0 | -2 | 0 | 1 |
31 Mar 22 | 0 | -2 | 0 | 1 |
31 Dec 21 | 0 | -2 | 0 | 1 |
30 Sep 21 | 0 | -2 | 0 | 1 |
30 Jun 21 | 0 | -2 | 0 | 1 |
31 Mar 21 | 0 | -2 | 0 | 1 |
31 Dec 20 | 0 | -2 | 0 | 1 |
Quality Earnings: GDTC is currently unprofitable.
Growing Profit Margin: GDTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GDTC is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare GDTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GDTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: GDTC has a negative Return on Equity (-36.76%), as it is currently unprofitable.